Analytical Data
-
Gene name
CACNa1H
- Application
-
Alternative Names
CACNa1H；Voltage-dependent T-type calcium channel subunit alpha-1H
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O95180
-
Expression Region
全长
-
AA Sequence
full
-
Molecular Weight
259 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CACNa1H, a member of the voltage-gated calcium channel family, plays a crucial role in the regulation of calcium ion influx in excitable tissues, particularly in the brain and heart. This protein is encoded by the CACNA1H gene and is associated with various physiological processes, including neurotransmitter release, muscle contraction, and synchronization of neuronal activity. Research has indicated that mutations or dysregulation of CACNa1H can lead to a range of pathological conditions, such as epilepsy, cardiac arrhythmias, and other calcium channel-related disorders. Given its importance in cellular signaling and electrical excitability, CACNa1H has garnered significant interest for its potential as a therapeutic target. The study of recombinant CACNa1H protein specifically aims to elucidate its functional mechanisms, investigate its role in disease, and facilitate the development of novel pharmacological agents. By producing recombinant forms of CACNa1H, researchers can explore structure-function relationships, assess the impact of specific mutations, and screen for compounds that modulate its activity. This research not only enhances our understanding of calcium channel physiology but also opens avenues for the design of targeted therapies for disorders linked to calcium signaling dysregulation. Overall, the investigation of CACNa1H recombinant protein is poised to contribute significantly to both basic science and clinical applications in neurology and cardiology.
